AJP - Regu Ad Instruments
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Regul Integr Comp Physiol 296: R618-R630, 2009. First published December 24, 2008; doi:10.1152/ajpregu.90417.2008
0363-6119/09 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
296/3/R618    most recent
90417.2008v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gabor, A.
Right arrow Articles by Leenen, F. H. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gabor, A.
Right arrow Articles by Leenen, F. H. H.

NEUROHUMORAL CONTROL OF CARDIOVASCULAR FUNCTION

Mechanisms in the PVN mediating local and central sodium-induced hypertension in Wistar rats

Alexander Gabor and Frans H. H. Leenen

Hypertension Unit, University of Ottawa Heart Institute, Ottawa, Ontario, Canada

Submitted 9 May 2008 ; accepted in final form 23 December 2008

Sympathoexcitatory and hypertensive responses to central infusion of Na+-rich artificial cerebrospinal fluid (aCSF) are enhanced by aldosterone and mediated by mineralocorticoid receptors (MRs) and benzamil-blockable Na+ influx, leading to "ouabain" release and ANG II type 1 (AT1) receptor stimulation. The present study evaluated the functional role of these mechanisms in the paraventricular nucleus (PVN). In conscious Wistar rats, Na+-rich aCSF was infused either directly into the PVN or intracerebroventricularly preceded by aldosterone and blockers. Infusion of Na+-rich aCSF in the PVN caused gradual increases in blood pressure (BP) and heart rate (HR). Aldosterone and a subpressor dose of ouabain in the PVN alone did not affect BP and HR but enhanced responses to Na+. Eplerenone, benzamil, and "ouabain"-binding Fab fragments only blocked the enhancement by aldosterone, whereas losartan blocked all responses to Na+-rich aCSF in the PVN. Increases in BP and HR by intracerebroventricular infusion of Na+-rich aCSF were enhanced by aldosterone infused intracerebroventricularly, but not in the PVN. Telmisartan in the PVN again blocked all responses. In contrast, both eplerenone and benzamil in the PVN did not change the pressor responses to intracerebroventricular infusion of aldosterone and Na+-rich aCSF. These findings indicate that AT1 receptors in the PVN mediate the responses to Na+-rich aCSF and their enhancement by aldosterone, both locally in the PVN or in the general CSF. MRs, benzamil-blockable Na+ channels or transporters, and "ouabain" can be functionally active in the PVN, but in Wistar rats appear not to contribute to the pressor responses to short-term increases in CSF [Na+].

brain; aldosterone; ouabain; angiotensin II type 1 receptors; blood pressure; paraventricular nucleus



Address for reprint requests and other correspondence: F. H. H. Leenen, Hypertension Unit, Univ. of Ottawa Heart Institute, H360, 40 Ruskin St., Ottawa, ON, Canada K1Y 4W7 (e-mail: fleenen{at}ottawaheart.ca)




This article has been cited by other articles:


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
X. Hou, S. F. Theriault, I. Dostanic-Larson, A. E. Moseley, J. B Lingrel, H. Wu, S. Dean, and J. W. Van Huysse
Enhanced pressor response to increased CSF sodium concentration and to central ANG I in heterozygous {alpha}2 Na+-K+-ATPase knockout mice
Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2009; 296(5): R1427 - R1438.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
A. Y. Bagrov, J. I. Shapiro, and O. V. Fedorova
Endogenous Cardiotonic Steroids: Physiology, Pharmacology, and Novel Therapeutic Targets
Pharmacol. Rev., March 1, 2009; 61(1): 9 - 38.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2009 by the American Physiological Society.